SCHEMBL378835

SCHEMBL378835

CC(=O)C(O)(C(=O)O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
KCNN4 O15554 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HIF1A Q16665 1/20 0.42
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2372942 1.00 CYP1A2 (0.46) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL2371928 1.00 CYP1A2 (0.46) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL2208136 0.85 CYP1A2 (0.54) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL6998732 0.83 CYP1A2 (0.43) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL10569602 0.83 CYP1A2 (0.43) CYP1A2CYP2D6MAPTKMT2AKCNN4
Acetamide SCHEMBL11005368 0.81 MAPT (0.53) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL7782499 0.81 CES1 (0.52) CYP1A2MAPTKMT2AKCNN4CYP2C19
SCHEMBL12083438 0.79 KCNN4 (0.60) MAPTKMT2AKCNN4HDAC3HDAC4
Methylamine SCHEMBL11005397 0.78 MAPT (0.55) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL10810428 0.78 HDAC3 (0.43) CYP1A2CYP2D6MAPTKMT2AKCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230160-A1 PROCESS FOR THE PREPARATION OF 4-((6BR,10AS)-3-METHYL-2,3,6B,9,10,10A-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-DE]QUINOXALIN-8-YL)-1-(4-FLUORO-PHENYL)-BUTAN-1-ONE AND INTERMEDIATES THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2025-07-17 US claimed
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 US claimed
CN-118021632-A Composition for promoting differentiation or proliferation of human adipose-derived stem cells 株式会社LG生活健康 2024-05-14 CN claimed
WO-2023195027-A1 PROCESS FOR THE PREPARATION OF 4-((6BR,10AS)-3-METHYL-2,3,6B,9,10,10A-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-DE]QUINOXALIN-8-YL)-1-(4-FLUORO-PHENYL)-BUTAN-1-ONE AND INTERMEDIATES THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2023-10-12 WO claimed
EP-4253366-A2 METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION Gilead Sciences, Inc. (US) 2023-10-04 EP claimed
US-11760746-B2 Methods and intermediates for preparing therapeutic compounds GILEAD SCIENCES, INC. (US) 2023-09-19 US claimed
CN-112055712-B Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections 吉利德科学公司 2023-07-14 CN claimed
EP-3610865-B1 COMPOSITION COMPRISING BENZOIC ACID AMIDE COMPOUND AND CYCLODEXTRIN SOLUBILIZING AGENT AMOREPACIFIC CORP (KR) 2023-07-12 EP claimed
EP-3752496-B1 METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION GILEAD SCIENCES INC (US) 2023-07-05 EP claimed
US-11673071-B2 Isotopic compositions BOTANICAL WATER TECHNOLOGIES IP LTD (GB) 2023-06-13 US claimed
US-9468278-B2 Hair colouring methods and kits thereof THE PROCTER & GAMBLE COMPANY (US) 2016-10-18 US claimed
EP-3036009-A1 HAIR COLOURING METHODS AND KITS THEREOF The Procter & Gamble Company (US) 2016-06-29 EP claimed
US-9358201-B2 Hair colouring methods and kits thereof THE PROCTER & GAMBLE COMPANY (US) 2016-06-07 US claimed
EP-2881143-A2 Hair colouring methods and kits thereof The Procter and Gamble Company (US) 2015-06-10 EP claimed
US-20150053228-A1 Hair Colouring Methods and Kits Thereof WELLA OPERATIONS US, LLC 2015-02-26 US claimed
WO-2015026991-A2 HAIR COLOURING METHODS AND KITS THEREOF THE PROCTER & GAMBLE COMPANY (US) 2015-02-26 WO claimed
WO-2015026994-A1 HAIR COLOURING METHODS AND KITS THEREOF THE PROCTER & GAMBLE COMPANY (US) 2015-02-26 WO claimed
US-20150053230-A1 Hair Colouring Methods and Kits Thereof WELLA OPERATIONS US, LLC 2015-02-26 US claimed
CN-101613666-B Bacillus and application thereof UNIV EAST CHINA SCIENCE & TECH 2011-01-19 CN claimed
CN-101613666-A One bacillus and purposes UNIV EAST CHINA SCIENCE & TECH 2009-12-30 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150053228-A1 Hair Colouring Methods and Kits Thereof COXFA4L2, ALPG, NACA CYP1A2 841/4885CYP2D6 923/4885MAPT 2094/4885
US-20250230160-A1 PROCESS FOR THE PREPARATION OF 4-((6BR,10AS)-3-METHYL-2,3,6B,9,10,10A-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-DE]QUINOXALIN-8-YL)-1-(4-FLUORO-PHENYL)-BUTAN-1-ONE AND INTERMEDIATES THEREOF CYP1B1, CYP4B1, CYP7A1 CYP1A2 20/4885CYP2D6 8/4885MAPT 3086/4885
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 CYP1A2 515/4885CYP2D6 71/4885MAPT 1009/4885
US-11760746-B2 Methods and intermediates for preparing therapeutic compounds CYP11A1, CYP11B1, CYP11B2 CYP1A2 525/4885CYP2D6 82/4885MAPT 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.